

<u>Protocol</u>	<u>Clinical Description</u>	<u>Medication</u>	<u>Brand (if applicable)</u>	<u>Drug formulary</u>	<u>Study Phase</u>	<u>Status</u>
BIO89-100-131	NASH	Pegozafermin		SQ injection	3	Enrolling
BIO89-100-132	NASH Cirrhosis	Pegozafermin		SQ injection	3	Enrolling
M23-784	Crohn's	Risankizumab	Skyrizi	SQ injection	3	Enrolling
ABX464-105	UC	ABX464		PO	3	Enrolling
ABX464-107	UC	ABX464		PO	3	Enrolling
AGMB-129-C102	Fibrotic Crohn's	AGMB-129		PO	2a	Enrolling
CORT118335-862	NASH	Miricorilant		PO	2b	Enrolling
CB8025-32251	PBC	seladelpar	Livedelzi	PO	3	Enrolling
CB8025-41837	PBC	seladelpar	Livedelzi	PO	3	Enrolling
GA45329	UC	RO7790121		IV, then SQ injection	3	Enrolling
ICPT 977-311	PBC	Obeticholic Acid and Bezafibrate	Ocaliva and bezafibrate	PO	3	Enrolling
CLIN-60190-463	PBC	Elafibranol	Iqirvo	PO	3	Enrolling
REC-4881-201	FAP	REC-4881		PO	1b/2	Enrolling
CB8025-31731	PBC	seladelpar	Livedelzi	PO	3	Enrolling
2021-01	HCC screening					enrolling
337HNAS20011	NASH	Ianifibranol		PO	3	enrolling
CLIN-60190-454	PBC	Elafibranol	Iqirvo	PO	3	enrolling
CNT01959CRD3005	Crohn's (fistula)	Guselkumab	Tremfya	IV, then SQ injection	3	enrolling
MGL-3196-18	NAFLD/Cirrhosis	Resmetirom	Rezdiffra	PO	3	enrolling
AT-01B-007	Hepatitis C	Bemnifosbuvir-Ruzasvir vs Sofosbuvir-Velpatasvir	vs Epclusa	PO	3	upcoming
GA45331	Crohn's	RO7790121		IV, then SQ injection	3	upcoming
ICPT 977-310	PBC	Obeticholic Acid and Bezafibrate	Ocaliva and bezafibrate	PO	3	upcoming
NGM 282-PS-231	PSC	Aldafermin		SQ injection	2b/3	upcoming
NAT-19	Gastroparesis	Naronapride			2b	upcoming
CRV-HCC-001	HCC Screening					upcoming